In this study, we focused on the potential of CXCL9 and TIS scores as immune signatures to identify patients at high risk for HER2-positive breast cancer, especially because both of these biomarkers are well known as predictors of ICI responses. The gene discussed is ERBB2; the disease is breast cancer.